EX-10.110-Q·CIK 1642380·0001642380-26-000014

First Amendment to Collaboration Agreement

View original filing on SEC EDGAR → ·  seen Nov 16, 2026, 16:00 EST

Exhibit 10.1

Certain information contained in this document, marked by brackets [***], has been omitted pursuant to Regulation S-K, Item 601(b)(10) because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.

FIRST AMENDMENT TO COLLABORATION AGREEMENT

This First Amendment to Collaboration Agreement (this “Amendment”) is entered into and made effective as of October 29, 2026 (the “Amendment Effective Date”), by and between Insight Molecular Diagnostics Inc. (formerly known as Oncocyte Corporation), a California corporation having a place of business at 2 International Plaza Drive, Suite 510, Nashville, Tennessee 37217 (“iMDx”), and Bio-Rad Laboratories, Inc., a Delaware corporation having a place of business at 1000 Alfred Nobel Drive, Hercules, California 94547 (“Bio-Rad”). Each of iMDx and Bio-Rad is referred to herein as a “Party” and collectively as the “Parties”.

RECITALS

A. Oncocyte Corporation (“Oncocyte”) and Bio-Rad entered into that certain Collaboration Agreement made effective as of April 5, 2024 (the “Agreement”).

B. Oncocyte and Bio-Rad entered into that certain binding Memorandum of Understanding, dated November 8, 2024, which identifies certain activities to be performed by the Parties with respect to pilot study sites outside the Territory (the “MOU”).

C. In June 2025, Oncocyte changed its corporate name from “Oncocyte Corporation” to “Insight Molecular Diagnostics Inc.”

D. The Agreement currently defines “Territory” to mean the United States and Germany, and the Parties now wish to expand the definition of “Territory” to include certain additional countries solely with respect to the RUO Assays (and not the IVD Kits), and to provide that such expanded definition will apply to the MOU from and after the Amendment Effective Date, in each case on the terms set forth in this Amendment.

NOW, THEREFORE, the Parties agree as follows:

1. Definitions. Capitalized terms used but not defined in this Amendment have the meanings given to them in the Agreement.

2. Name Change. The Parties acknowledge the change of Oncocyte’s corporate name to Insight Molecular Diagnostics Inc. From and after the date of such name change, all references in the Agreement and the MOU to “Oncocyte” or “Oncocyte Corporation” shall be deemed to refer to iMDx, and all defined terms in the Agreement and the MOU that include the word “Oncocyte” (including “Oncocyte Indemnified Party,” “Oncocyte Materials” and “Oncocyte Product Arising IP”) shall continue to apply to iMDx. The Parties agree that such name change did not constitute an assignment of the Agreement or the MOU.

1


3. Amendment to Definition of “Territory”. Article I (Definitions) of the Agreement is hereby amended by deleting the definition of “Territory” in its entirety and replacing it with the following:

“Territory” means the United States, [***], Germany, [***]; provided, however, that solely with respect to the IVD Kits, the IVD Kits Option and the IVD Phase (including for purposes of Section 6.2 (IVD Kits), Section 6.3 (Regulatory Diligence), Section 6.6 (Post-Market Activities) and any other provision of this Agreement to the extent relating to the IVD Kits), “Territory” means the United States and Germany.

As used in this Amendment, “Additional Countries” means [***].

4. Effect of Expanded Territory. Without limiting the generality of Section 3, the Parties acknowledge and agree that, from and after the Amendment Effective Date:

(a) iMDx shall have the exclusive right to make and book all sales of the RUO Assays in the Additional Countries in accordance with Section 5.1(b) (Commercialization of Products Within the Territory) of the Agreement, and Bio-Rad shall have no further rights or obligations with respect to the Additional Countries under Section 3.2(a)(i), Section 5.1(c) (Commercialization of Products Outside the Territory; Supply Payments), Section 6.1(b) (Regulatory Compliance) (as it relates to outside the Territory) or Section 7.2 (Resale Supply Payments) of the Agreement;

(b) Net Sales of the RUO Assays in the Field in the Additional Countries shall be subject to the Royalty Payments and the reporting obligations set forth in Section 7.1 (Royalty Payments) of the Agreement, and to Sections 7.3 through 7.9 of the Agreement;

(c) Bio-Rad shall have the exclusive right to sell the Bio-Rad ddPCR Instruments and Reagents in the Additional Countries in accordance with Section 5.1(a) (Supply of Bio-Rad ddPCR Instruments and Reagents) of the Agreement, and iMDx shall market, promote, sell, offer to sell and commercialize the RUO Assays in the Additional Countries solely and exclusively with the use of Bio-Rad ddPCR Instruments and Reagents;

(d) iMDx shall be responsible for the Regulatory Compliance for the RUO Assays in the Additional Countries in accordance with Section 6.1(b) (Regulatory Compliance) of the Agreement;

(e) the last sentence of Section 9.2 (Relevant Third Party IP) of the Agreement is hereby amended and restated in its entirety to read as follows: “Notwithstanding anything contained in this Agreement to the contrary and for the avoidance of doubt, Oncocyte shall be responsible for the defense of any allegations or claims that the RUO Assays infringe the Intellectual Property Rights of a Third Party within the United States, the European Union and any other country in the Territory, and Bio-Rad shall have sole responsibility for defense outside of the United States, the European Union and the Territory in any country in which it markets, sells or distributes the RUO Assays.”;

2


(f) the Parties shall, through the JSC, update the Product Commercialization Plan as necessary to reflect the expanded Territory; and

(g) for clarity, the expansion of the Territory under this Amendment applies solely to the RUO Assays, and nothing in this Amendment modifies or limits (i) the IVD Kits Option or any of Bio-Rad’s rights under Section 8.2 (Option for IVD Kits) of the Agreement, or (ii) Bio-Rad’s designation as the Manufacturer of Record for, or Bio-Rad’s ownership of the Regulatory Submissions and Regulatory Approvals for, the IVD Kits in any country other than the United States and Germany, including the Additional Countries.

5. Application to the MOU.

(a) Notwithstanding anything to the contrary in the MOU, from and after the Amendment Effective Date, each reference in the MOU to the “Territory” shall mean the Territory as defined in the Agreement as amended by this Amendment, and each reference in the MOU to the “Agreement” shall mean the Agreement as amended by this Amendment. For all periods prior to the Amendment Effective Date, the term “Territory” as used in the MOU shall continue to have the meaning given to it in the Agreement prior to this Amendment (i.e., the United States and Germany).

(b) Each institution identified on Appendix A to the MOU as of the Amendment Effective Date that is located in the Territory shall, as of the Amendment Effective Date, (i) cease to be a Pilot Site under the MOU and be deemed removed from Appendix A to the MOU, and (ii) be treated as a customer located in the Territory for all purposes of the Agreement. Accordingly, as of the Amendment Effective Date, Bio-Rad shall have no further obligations under the MOU with respect to such institutions, and any sales of RUO Assays by iMDx to such institutions shall be governed by the Agreement (including Section 5.1(b) and Article VII (Payments)) and not the MOU.

(c) Any Royalty Payments or other obligations accrued under the MOU prior to the Amendment Effective Date, including with respect to Net Sales of RUO Assays to any Pilot Site prior to the Amendment Effective Date, shall not be affected by this Amendment.

(d) Except as expressly set forth in this Section 5, the MOU remains unchanged and in full force and effect.

6. Miscellaneous.

(a) Effect of Amendment. Except as expressly amended by this Amendment, the Agreement remains unchanged and in full force and effect. From and after the Amendment Effective Date, each reference in the Agreement to “this Agreement,” “hereunder,” “hereof” or words of similar import shall mean and be a reference to the Agreement as amended by this Amendment. In the event of any conflict between the terms of this Amendment and the terms of the Agreement or the MOU, the terms of this Amendment shall control.

(b) Governing Law; Jurisdiction. This Amendment shall be governed by, and construed and enforced in accordance with, Section 15.3 (Governing Law; Jurisdiction) of the Agreement, which is incorporated herein by reference, mutatis mutandis.

3


(c) Entire Agreement. This Amendment, together with the Agreement and the MOU, constitutes the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, both written and oral, with respect thereto.

(d) Counterparts. This Amendment may be executed (including via DocuSign, facsimile or other reliable electronic means of transmitting signed copies, such as emailed scanned signed copies) in any number of counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.

[Signature Page Follows]

4


IN WITNESS WHEREOF, the Parties, through their duly authorized representatives, have executed this Amendment as of the Amendment Effective Date.

INSIGHT MOLECULAR DIAGNOSTICS INC.By: /s/ Joshua RiggsName: Joshua RiggsTitle: Chief Executive OfficerDate: October 28, 2026 BIO-RAD LABORATORIES, INC.By: /s/ Scott CrowderName: Vice President, Business DevelopmentTitle: Vice President, Business DevelopmentDate: October 29, 2026

5


Back to all agreements